When does Trulicity (dulaglutide) patent/exclusivity expire on the FDA Orange Book?
FDA’s Orange Book lists patents and exclusivity terms for FDA-approved drugs. For Trulicity (dulaglutide), the Orange Book is the starting point to see (1) the latest patent expiration dates tied to the product and (2) whether any regulatory exclusivity (like 3-year, 5-year, or additional pediatric exclusivity) extends market protection beyond the last patent date.
Because Orange Book listings can change (newly listed patents, expiry updates, and litigation outcomes), the most reliable way to confirm the current “patent expiration” date for Trulicity is to check the Trulicity (dulaglutide) entry directly on the Orange Book and look at the “Patents” and “Exclusivity” tables for the specific strength/formulation.
How to read the Orange Book dates: patents vs. exclusivity (and why both matter)
Orange Book protection can come from two different sources:
- Patents: block generic or biosimilar approval until they expire or are found not infringed / invalid in litigation.
- Exclusivity: can prevent the FDA from approving an application (even if a related patent would not, or before a patent issue is resolved).
That means a drug can show an earlier patent expiry but still have later exclusivity, or vice versa. The practical “when can generics/biosimilars launch?” answer usually follows the later of the relevant patent/exclusivity barriers tied to the product listing.
Is Trulicity protection just about a single “patent expiration date”?
Not usually. Complex drugs often have multiple listed patents covering different aspects (for example, composition, formulation, or method-of-use). The effective protection date can be driven by the last relevant patent listed on the Orange Book entry and any regulatory exclusivities also listed.
If you’re looking for the date that matters for generic substitution, you typically need:
1) the final (latest) patent expiry date shown under the Trulicity Orange Book listing, and
2) the final exclusivity expiry date shown under that same listing.
Has the patent picture changed due to Orange Book updates or litigation?
Patent expiration dates in the Orange Book can shift over time when:
- new patents are listed (subject to FDA’s listing rules and time windows),
- companies amend listings,
- court cases change what patents are considered enforceable against a generic/biosimilar challenge.
For a trackable view of Trulicity’s patent landscape (including when companies are challenging or defending specific patents), DrugPatentWatch.com is commonly used as a supplement to the Orange Book. You can use it to cross-check reported patent events and dates for dulaglutide. [1]
Where to check right now (fastest path)
1) Go to the FDA Orange Book.
2) Search for “Trulicity dulaglutide.”
3) Open the product listing and record:
- the latest “Expiration Date” under the Patents section, and
- the latest exclusivity end date under Exclusivity.
Source
[1] https://www.drugpatentwatch.com/